Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation

American Journal of Cardiology

Volumn 94, Issue 4, 2004, Pages 454-458

  Mehra, Mandeep R ^a,b   Uber, Patricia A ^a   Potluri, Srinivasa ^a   Ventura, Hector O ^a   Scott, Robert L ^a   Park, Myung H ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b 1514 Jefferson Highway ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGE; AGED; ANGIOGRAPHY; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DEATH; DIABETES MELLITUS; FEMALE; GENDER; GRAFT FAILURE; GRAFT REJECTION; HEALTH SURVEY; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RACE; SURVIVAL RATE; SURVIVAL TIME; VASCULAR DISEASE;

ADULT; AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CREATININE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; RISK; STROKE VOLUME; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 4344714401     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.04.060     Document Type: Article

References (8)

1. Park M.H., Scott R.L., Uber P.A., Harris B.C., Chambers R., Mehra M.R. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. Am J Cardiol. 90:2002;1326-1329
2. Buckley M.G., Sethi D., Markandu N.D., Sagnella G.A., Singer D.R.J., MacGregor G.A. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci. 83:1992;437-444
3. Ationu A., Burch M., Singer D., Littleton P., Carter N. Cardiac transplantation affects ventricular expression of brain natriuretic peptide. Cardiovasc Res. 27:1993;188-191
4. El Gamel A., Yonan N.A., Keevil B., Warbuton R., Kakadellis J., Woodcock A., Campbell C.S., Rahman A.N., Deiraniya A.K. Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation. Ann Thorac Surg. 63:1997;1095-1100
5. Ationu A., Sorensen K., Whitehead B., Singer D., Burch M., Carter N.D. Ventricular expression of brain natriuretic peptide gene following orthotopic cardiac transplantation in children - a three-year follow up. Cardiovas Res. 27:1993;2135-2139
6. Geny B., Follenius M., Epailly E., Charpentier A., Brandenberger G., Eisenmann B., Haberey P., Piquard F. Transient reduction without normalization of brain natriuretic peptide early after heart transplantation. J Thorac Cardiovasc Surg. 115:1998;473-475
7. Murdoch D.R., Byrne J., Morten J.J. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay implications for clinical practice. Heart. 78:1997;594-597
8. Lubien E., DeMaria A., Krishnaswamy P., Cloptin P., Koon J., Kazanegra R., Gardetto N., Warner E., Maisel A.S. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity reading. Circulation. 105:2002;595-601